Goldman Sachs Starts Pharmacyclics (PCYC) at Neutral
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs initiates coverage on Pharmacyclics (NASDAQ: PCYC) with a Neutral rating and $80 price target.
Despite ever-increasing competition, the firm sees peak ibrutinib sales of approx. $6 billion. However, the firm said this opportunity is reflected in the share price.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $76.54 yesterday.
Despite ever-increasing competition, the firm sees peak ibrutinib sales of approx. $6 billion. However, the firm said this opportunity is reflected in the share price.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $76.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
